Nowadays, lots of ongoing efforts have been conducted in identifying potential therapeutics targeting the above-mentioned effectors (ERK, AKT-mTOR and STAT3), which are frequently dysregulated in NSCLC. The gene discussed is STAT3; the disease is non-small cell lung carcinoma.